Details

Last Funding Type

Series A

Last Funding Money Raised

¥100M

Industries

Biotechnology,Pharmaceutical,Product Research,Therapeutics

Founded date

Jan 1, 2017

Number Of Employee

51 - 100

Operating Status

Active

Novamab focuses on the research and development of new nanobodies. The core members of the team have 15 years of experience in nanobody research and development, and are domestic nanobody "pioneers". At present, they have established an inhaled macromolecular drug research and development platform, an albumin nanobody long-acting platform and a nanobody double-antibody platform, etc., to give full play to nanobody The advantages of antibodies, the development of innovative nanobody drugs such as sprays and eye drops, to solve the pain points of clinical major chronic diseases in terms of administration methods, administration cycles, etc.